Reply to N. Personeni et al

Affiliations

Comment

Richard Jackson et al. J Clin Oncol. 2017.

. 2017 Jul 1;35(19):2214-2215.

doi: 10.1200/JCO.2017.72.9293. Epub 2017 May 4.

¹ Richard Jackson, Efty Psarelli, and Philip J. Johnson, University of Liverpool, Liverpool, United Kingdom.

No abstract available

Comment on

Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials.
Jackson R, Psarelli EE, Berhane S, Khan H, Johnson P. Jackson R, et al. J Clin Oncol. 2017 Feb 20;35(6):622-628. doi: 10.1200/JCO.2016.69.5197. Epub 2017 Jan 3. J Clin Oncol. 2017. PMID: 28045619
Sorafenib in Hepatitis C Virus-Negative Patients With Hepatocellular Carcinoma: Don't Throw the Baby Out With the Bathwater!
Personeni N, Rimassa L, Giordano L, Santoro A. Personeni N, et al. J Clin Oncol. 2017 Jul 1;35(19):2213-2214. doi: 10.1200/JCO.2017.72.7776. Epub 2017 May 4. J Clin Oncol. 2017. PMID: 28471708 No abstract available.